Free Trial
NYSE:FNA

Paragon 28 Q4 2024 Earnings Report

Paragon 28 logo
$13.10 +0.02 (+0.11%)
Closing price 04/17/2025
Extended Trading
$13.10 0.00 (0.00%)
As of 04/17/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Paragon 28 EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.12
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Paragon 28 Revenue Results

Actual Revenue
$71.75 million
Expected Revenue
$70.81 million
Beat/Miss
Beat by +$937.00 thousand
YoY Revenue Growth
N/A

Paragon 28 Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 6, 2025
Conference Call Time
4:00PM ET

Earnings Documents

Paragon 28 Earnings Headlines

3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
Zimmer acquires Paragon 28 in $1.2bn deal
See More Paragon 28 Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Paragon 28? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Paragon 28 and other key companies, straight to your email.

About Paragon 28

Paragon 28 (NYSE:FNA) (NYSE: FNA) is a medical device company specializing in comprehensive solutions for foot and ankle surgery. Headquartered in Englewood, Colorado, the company develops, manufactures, and markets a diverse range of implants, instruments and digital platforms to support orthopedic surgeons. Since its founding in 2019, Paragon 28 has focused on delivering clinically driven products designed to address both routine and complex pathologies of the lower extremity.

The company’s product portfolio includes plating systems, intramedullary nails, compression staples, external fixation devices and patient-specific instrumentation. Paragon 28 also offers proprietary digital preoperative planning and post-operative monitoring tools that allow surgeons to tailor treatment plans, optimize implant selection and track patient outcomes. These integrated solutions are intended to enhance surgical precision, reduce operating room time and improve overall case efficiency.

With a global footprint, Paragon 28 serves hospitals, ambulatory surgery centers and physician practices across North America, Europe, Asia-Pacific and the Middle East. The company distributes its products through a combination of direct sales teams and regional distribution partners, investing in clinical education programs, cadaver labs and advisory boards to support surgeon training and adoption. Paragon 28’s international expansion has been driven by strategic partnerships and targeted product launches aligned with regional regulatory requirements.

Under the leadership of President and Chief Executive Officer Michael Macioci, Paragon 28 emphasizes a culture of innovation and collaboration. The company’s executive team and board of directors include experienced professionals from the orthopedic and medical technology sectors. Paragon 28 continues to pursue research and development initiatives aimed at refining surgical workflows and advancing next-generation implant technologies, while maintaining close engagement with key opinion leaders and academic institutions.

View Paragon 28 Profile

More Earnings Resources from MarketBeat